This custom 15-gene NGS panel covers the activating and drug resistance hotspot DNA point mutations and indels in EGFR, KRAS, NRAS, BRAF, PIK3CA, ERBB2, MET, KIT, PDGFRA, ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 genes which serve as biomarkers for guiding treatment decisions in NSCLC patients. This evidence concerns the gene NTRK2 and non-small cell lung carcinoma.